Literature DB >> 29174676

Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines.

Samuel Cibulski1, Mariana Rivera-Patron2, Norma Suárez2, Macarena Pirez3, Silvina Rossi4, Anna Carolina Yendo5, Fernanda de Costa5, Grace Gosmann6, Arthur Fett-Neto7, Paulo Michel Roehe8, Fernando Silveira9.   

Abstract

Saponin-based adjuvants are promising adjuvants that enhance both humoral and T-cell-mediated immunity. One of the most used natural products as vaccine adjuvants are Quillaja saponaria bark saponins and its fraction named Quil A®. Despite that, its use has been restricted for human use due to safety issues. As an alternative, our group has been studying the congener species Quillaja brasiliensis saponins and its performance as vaccine adjuvants, which have shown to trigger humoral and cellular immune responses comparable to Quil A® but with milder side effects. Here, we studied a semi purified aqueous extract (AE) and a previously little characterized saponin-enriched fraction (QB-80) from Q. brasiliensis as vaccine adjuvants and an inactivated virus (bovine viral diarrhea virus, BVDV) antigen co-formulated in experimental vaccines in mice model. For the first time, we show the spectra pattern of the Q. brasiliensis saponins by MALDI-TOF, a novel and cost-effective method that could be used to characterize different batches during saponins production. Both AE and QB-80 exhibited noteworthy chemical similarities to Quil A®. In addition, the haemolytic activity and toxicity were assessed, showing that both AE and QB-80 were less toxic than Quil A®. When subcutaneously inoculated in mice, both fractions promoted long-term strong antibody responses encompassing specific IgG1 and IgG2a, enhanced the avidity of IgG antibodies, induced a robust DTH reaction and significantly increased IFN-ɣ production in T CD4+ and T CD8+ cells. Furthermore, we have proven herein that AE has the potential to promote dose-sparing, substantially reducing the dose of antigen required for the BVDV vaccines and still eliciting a mixed Th1/Th2 strong immune response. Based on these results, and considering that AE is a raw extract, easier and cheaper to produce than commercially available saponins, this product can be considered as candidate to be escalated from experimental to industrial uses.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvants; BVDV; Dose-sparing; Humoral and cellular responses; Quillaja brasiliensis; Saponins

Mesh:

Substances:

Year:  2017        PMID: 29174676     DOI: 10.1016/j.vaccine.2017.11.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Formulation of IMXQB: Nanoparticles Based on Quillaja brasiliensis Saponins to be Used as Vaccine Adjuvants.

Authors:  Mariana Rivera-Patron; Samuel P Cibulski; Iris Miraballes; Fernando Silveira
Journal:  Methods Mol Biol       Date:  2022

2.  Structure Elucidation of Triterpenoid Saponins Found in an Immunoadjuvant Preparation of Quillaja brasiliensis Using Mass Spectrometry and 1H and 13C NMR Spectroscopy.

Authors:  Federico Wallace; Carolina Fontana; Fernando Ferreira; Cristina Olivaro
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

3.  Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation.

Authors:  Samuel Cibulski; Ana Paula Muterle Varela; Thais Fumaco Teixeira; Martín Pablo Cancela; Patrícia Sesterheim; Diogo Onofre Souza; Paulo Michel Roehe; Fernando Silveira
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

4.  ISCOM-Matrices Nanoformulation Using the Raw Aqueous Extract of Quillaja lancifolia (Q. brasiliensis).

Authors:  Samuel Cibulski; Fernando Silveira; Thalisson Amorim de Souza; Joanda Paola Raimundo; Yuri Mangueira Nascimento; Lucas Silva Abreu; Norma Suarez; Iris Miraballes; Paulo Michael Roehe; Demetrius Antonio Machado de Araújo; Josean Fechine Tavares; Marcelo Sobral da Silva
Journal:  Bionanoscience       Date:  2022-08-06

5.  Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.

Authors:  Amir Ghaemi; Parisa Roshani Asl; Hedieh Zargaran; Delaram Ahmadi; Asim Ali Hashimi; Elahe Abdolalipour; Sahar Bathaeian; Seyed Mohammad Miri
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

6.  Safety and Efficacy of the Bordetella bronchiseptica Vaccine Combined with a Vegetable Oil Adjuvant and Multi-Omics Analysis of Its Potential Role in the Protective Response of Rabbits.

Authors:  Xuemei Cui; Xiangfei Xu; Pan Huang; Guolian Bao; Yan Liu
Journal:  Pharmaceutics       Date:  2022-07-08       Impact factor: 6.525

7.  Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses.

Authors:  Samuel Paulo Cibulski; Mariana Rivera-Patron; Gustavo Mourglia-Ettlin; Cecilia Casaravilla; Anna Carolina Alves Yendo; Arthur Germano Fett-Neto; José Alejandro Chabalgoity; María Moreno; Paulo Michel Roehe; Fernando Silveira
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.